Advertisement

Commercialization and Entrepreneurship

  • Daria Mochly-RosenEmail author
  • Kevin Grimes
Chapter
Part of the SpringerBriefs in Pharmaceutical Science & Drug Development book series (BRIEFSPSDD)

Abstract

As academic researchers, some of us may be interested in forming start-up companies to develop and market the drugs that are based on our research. Others may be happy to license our technology and findings to an existing company. Knowing how to evaluate potential drug markets and effectively pitch to investors will help both groups of academicians. With so much intellectual property generated in academia, a well-researched commercial assessment and an organized and effective pitch can make potential licensees or investors take notice. The goal is not to recapitulate the sophisticated marketing plans drawn up in industry, but to highlight the project’s potential and show some industry savvy. This chapter provides guidance on evaluating the commercial potential of the project, pitching to potential licensees, approaching venture capitalists, and funding the development of not-for-profit programs. The chapter also discusses legal and practical considerations, should the academic decide to form a start-up company.

Keywords

Venture Capital Visceral Leishmaniasis Initial Public Offering Business Entity Product Share 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
  2. 2.
    CDC press release recommending hepatitis C testing for US baby boomers. http://www.cdc.gov/nchhstp/newsroom/2012/HCV-Testing-Recs-PressRelease.html
  3. 3.
    Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R (2009) Advancing drug innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop Dis 3(8):e440PubMedCrossRefGoogle Scholar
  4. 4.
    Moran M (2005) A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoS Med 2(9):e302PubMedCrossRefGoogle Scholar
  5. 5.
    Emmert-Buck MR (2011) An NIH intramural percubator as a model of academic-industry partnerships: from the beginning of life through the valley of death. J Transl Med 9:54PubMedCrossRefGoogle Scholar
  6. 6.
    Moos WH, Kodukula K (2011) Nonprofit pharma: solutions to what ails the industry. Curr Med Chem 18(22):3437–3440PubMedCrossRefGoogle Scholar
  7. 7.
    Olliaro P, Seiler J, Kuesel A, Horton J, Clark JN, Don R, Keiser J (2011) Potential drug development candidates for human soil-transmitted helminthiases. PLoS Negl Trop Dis 5(6):e1138PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Chemical and Systems BiologyStanford University School of MedicineStanfordUSA
  2. 2.Chemical and Systems BiologyStanford University School of MedicineStanfordUSA

Personalised recommendations